Midodrine

Midodrine is a synthetic sympathomimetic amine classified as a selective agonist of the alpha-1 adrenergic receptor. It is a prodrug, meaning it is inactive as swallowed and is converted by enzymatic breakdown in the body into its pharmacologically active form, desglymidodrine ^[1]. Because this active metabolite crosses poorly into the brain and does not stimulate the heart's beta receptors, its actions are largely confined to the peripheral blood vessels ^[1].

The compound was described in the early 1970s and gained approval from the United States Food and Drug Administration in 1996 for symptomatic orthostatic hypotension. That approval came through an accelerated pathway on the condition that further confirmatory studies be completed; when the follow-up trials were slow to appear, the agency proposed withdrawing the drug in 2010, a move that alarmed patients who depended on it and was ultimately reversed while additional evidence was assembled ^[4][5]. Midodrine is a prescription-only medicine sold under names including ProAmatine, Gutron and Amatine, and inexpensive generic tablets are now widely available ^[1].

The principal use of midodrine is to relieve orthostatic hypotension, a condition in which blood pressure drops sharply on standing and produces dizziness, light-headedness, blurred vision or fainting ^[4]. It is regarded as a first-line pharmacological option, often used alongside droxidopa and fludrocortisone, and applies to both neurogenic forms (in which the autonomic nerves are damaged, as in Parkinson disease and related disorders) and non-neurogenic forms ^[3][4]. A Bayesian meta-analysis of randomized trials found that midodrine raised standing systolic blood pressure to a greater degree than droxidopa, although it also carried a higher risk of supine hypertension, meaning elevated pressure while lying down ^[2]. Beyond its primary indication, the drug has been studied and used off-label for low blood pressure during hemodialysis, for the hepatorenal syndrome, for postural orthostatic tachycardia syndrome and for certain forms of urinary incontinence ^[4].

In practice midodrine is supplied as oral tablets taken during waking hours, with the final daily dose scheduled well before lying down to limit supine hypertension ^[1]. Treatment is generally paired with non-drug measures such as increased salt and fluid intake, compression garments and physical counter-maneuvers, and the aim is to reduce symptoms and improve daily functioning rather than to normalize blood pressure readings ^[3][4].

Midodrine is prescription only. Its signature risk is supine hypertension, a dangerous rise in blood pressure when lying down, which is why doses are given during upright daytime hours and never within about four hours of bedtime. Common side effects reflect its vessel-tightening action, including goosebumps, scalp tingling or itching, chills, and urinary urgency or retention. It should be avoided in severe heart disease, sudden kidney failure, untreated urinary retention, pheochromocytoma and overactive thyroid. Blood pressure should be checked both sitting or standing and lying down to make sure the daytime benefit does not turn into nighttime harm.

Midodrine is a prodrug for desglymidodrine, an alpha-1 agonist that raises peripheral vascular resistance, so its interactions follow that single mechanism closely.

Other vasoconstrictors add to it directly. Phenylephrine, pseudoephedrine, ephedrine and ergot derivatives produce excessive pressure rises, and because midodrine's effect does not switch off when you lie down, supine hypertension is the usual way this shows up. Fludrocortisone, often used for the same indication, adds volume expansion on top of vasoconstriction and compounds the supine problem. Monoamine oxidase inhibitors amplify sympathomimetic pressor responses generally.

Alpha-1 antagonists work against it at the receptor itself. Doxazosin, prazosin, terazosin, tamsulosin and silodosin blunt or abolish the pressure response.

The less obvious interaction is on heart rate. The rise in blood pressure triggers a reflex vagal slowing, so adding drugs that also slow the heart, digoxin, beta blockers and non-dihydropyridine calcium channel blockers such as verapamil or diltiazem, can produce marked bradycardia or atrioventricular block.

Checking a whole stack? Run it through interactions + stacks.

Midodrine is a synthetic alpha-1 adrenergic agonist developed as a peripherally acting vasopressor, designed as a prodrug that is converted in the body to its active metabolite, desglymidodrine. It was used in Europe for years under the trade name Gutron before gaining approval in the United States in 1996, where it was marketed as ProAmatine for the treatment of symptomatic orthostatic hypotension, the drop in blood pressure that occurs on standing.

Its United States approval was granted through an accelerated pathway based on a surrogate measure, the improvement in standing blood pressure demonstrated in a pivotal randomized trial by the Midodrine Study Group, with confirmatory clinical-benefit studies expected to follow. When those confirmatory trials were slow to materialize, the Food and Drug Administration proposed withdrawing the drug in 2010, a move that prompted concern from patients and clinicians and was ultimately reversed, allowing midodrine to remain available. It is now a widely used generic and a standard option for orthostatic hypotension.

Midodrine occupies a valued niche as one of the few oral drugs that can reliably raise blood pressure in people who faint or feel faint on standing, offering real relief for a problem that is otherwise difficult to manage. Its design is clever: because its active form acts on blood vessels in the periphery and penetrates the brain poorly while largely leaving the heart's own receptors alone, it narrows vessels and lifts standing blood pressure without directly driving the heart rate.

That targeted action, backed by a well-conducted randomized trial showing consistent improvement in both blood pressure and symptoms, has made it a mainstay for neurogenic orthostatic hypotension and a useful tool in related conditions. The honest caveats are straightforward: because it raises pressure regardless of posture, it can cause supine hypertension, so it is taken during waking hours and not near bedtime, and doses are timed around activity. The very fact that patients and physicians rallied to keep it on the market speaks to how genuinely useful this small, well-understood molecule has proven to be.